Company intelligence / Profile preview

Amplitude Therapeutics

Boston, Massachusetts, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Amplitude Therapeutics is a seed-stage biotechnology company developing next-generation RNA therapies. The company’s current work includes using trans-amplifying RNA to enable low-cost production of monoclonal antibodies for the prevention of infectious diseases. Backed by leading biotech VCs and supported by a Gates Foundation grant, the company is in early preclinical stages with no reported clinical results yet.

Therapeutic areas: Infectious Diseases
Modalities: RNA therapytrans-amplifying RNAMonoclonal antibody
Industry: Biotech

Partnerships

Bill & Melinda Gates Foundation

Beyond the preview

Go deeper on Amplitude Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amplitude Therapeutics.

Explore the full profile